Novo Nordisk

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

News

WhatsApp lands Moderna in hot water with PMCPA

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo

News

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made

News

Novo Nordisk closes on EU okay for haemophilia antibody

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia.

News

Lawmaker asks FTC to probe Novo/Catalent deal

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operate

R&D